Functional antibody patent claims are a powerful tool to protect therapeutic antibodies, the most important and valuable drugs of our time. The broad scope of protection these claims offer is also the reason for an ongoing controversy, because what patent owners appreciate is considered a threat to innovation by competitors.
Functional antibody claims, in particular epitope based claims, have been subject to extensive court litigation, and were repeatedly declared dead in the past. But it might be too early to sing that swan song. Panelists will discuss pros and cons of this claim species, give an insight into the status quo of granting policy in Europe and the United States and provide insights into the technical approaches that applicants and competitors may use to determine whether or not the respective epitope based claim is novel, or whether a given candidate antibody falls under the scope of one such patent.

Ability Level: All

Session ID: 19746